Discovery of a dual-target CRBN-mediated degrader for IKZF1/3 and GSPT1 proteins
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2025.109367 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Chunchao Tang und 5 weiteren Autor:innen. Beteiligte Einrichtung: College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China. Hauptthemen laut MEDLINE: Ikaros Transcription Factor, Antineoplastic Agents, Ubiquitin-Protein Ligases, Adaptor Proteins, Signal Transducing. Die Arbeit nennt 47 Literaturangaben.
Abstract (Originalsprache)
The overexpression of IKZF1/3 (Ikaros and Aiolos) and GSPT1 (G1 to S phase transition protein 1) is closely linked to hematologic malignancies. Immunomodulatory drugs (IMiDs) like lenalidomide and pomalidomide degrade IKZF1/3 and are combined with other therapies to treat hematologic malignancies, including multiple myeloma and non-Hodgkin lymphoma. GSPT1 has emerged as a promising therapeutic target for blood cancers. Developing dual degraders targeting both IKZF1/3 and GSPT1 could synergistically enhance efficacy and improve treatment outcomes. This study identified a novel molecular glue degrader, DIX-01, which simultaneously targets and degrades IKZF1/3 and GSPT1 proteins. DIX-01 exhibited potent cytotoxicity in multiple cancer cell lines (22Rv1, MV4-11, HL-60, MOLM13), with IC50 values in the nanomolar range. Western blot analysis confirmed time-dependent and concentration-dependent degradation of IKZF1/3 and GSPT1. Proteomic analysis confirmed the targeted protein degradation by DIX-01, while transcriptomic sequencing further elucidated its modulation of signaling pathways. Molecular docking studies suggested that DIX-01 may form stable ternary complexes with CRBN-IKZF1 and CRBN-GSPT1, providing a structural basis for its dual-target degradation activity. Furthermore, DIX-01 significantly inhibited tumor growth in a zebrafish xenograft model transplanted with human acute myeloid leukemia cells (MV4-11), supporting its potential as a therapeutic agent for hematologic malignancies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou 730000, China.
- School of Medicine and Pharmacy, Ocean University of China, Qingdao 266003, China.
- Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao 999078, China.
- Suzhou Degen Bio-medical Co., Ltd, No.1 Hua yun Road, SIP, Suzhou 215000, China.
- Qingdao Shark VNARs Development Technology Innovation Center, College of Biological Engineering, Qingdao University of Science and Technology, Qingdao, 266042, China. Electronic address: guych@126.com.
- Centre for Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao 999078, China. Electronic address: xjyao@mpu.edu.mo.
Zitieren
APA
Tang, C., Li, Z., Lu, R., Yu, G., Gu, Y., & Yao, X. (2026). Discovery of a dual-target CRBN-mediated degrader for IKZF1/3 and GSPT1 proteins. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109367
Vancouver
Tang C, Li Z, Lu R, Yu G, Gu Y, Yao X. Discovery of a dual-target CRBN-mediated degrader for IKZF1/3 and GSPT1 proteins. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2025.109367
BibTeX
@article{Tang2026,
author = {Tang, Chunchao and Li, Zhen and Lu, Ruiqiang and Yu, Guangliang and Gu, Yuchao and Yao, Xiaojun},
title = {Discovery of a dual-target CRBN-mediated degrader for IKZF1/3 and GSPT1 proteins},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2025.109367}
}
EUVIMED